Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R.

J Clin Invest. 2013 Jun 3;123(6):2447-63. Erratum in: J Clin Invest. 2013 Nov;123(11):4980.

PMID:
23728179
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.

Houot R, Levy R.

Blood. 2009 Apr 9;113(15):3546-52. doi: 10.1182/blood-2008-07-170274. Epub 2008 Oct 21.

PMID:
18941113
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.

Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, Timmerman JM.

J Immunother. 2012 Sep;35(7):534-43. doi: 10.1097/CJI.0b013e318261e679.

PMID:
22892450
[PubMed - indexed for MEDLINE]
4.

Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.

Sharma S, Dominguez AL, Manrique SZ, Cavallo F, Sakaguchi S, Lustgarten J.

Cancer Res. 2008 Sep 15;68(18):7530-40. doi: 10.1158/0008-5472.CAN-08-1635.

PMID:
18794141
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG.

PLoS One. 2008 Apr 23;3(4):e1983. doi: 10.1371/journal.pone.0001983.

PMID:
18431473
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.

Geary SM, Lemke CD, Lubaroff DM, Salem AK.

Cancer Immunol Immunother. 2011 Sep;60(9):1309-17. doi: 10.1007/s00262-011-1038-y. Epub 2011 May 28.

PMID:
21626029
[PubMed - indexed for MEDLINE]
7.

Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.

Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD.

Cancer Res. 2004 Aug 1;64(15):5407-14.

PMID:
15289349
[PubMed - indexed for MEDLINE]
Free Article
8.

Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.

Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B.

Clin Cancer Res. 2010 Jul 1;16(13):3399-408. doi: 10.1158/1078-0432.CCR-09-3087. Epub 2010 Jun 22.

PMID:
20570924
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH.

J Immunother. 2010 Apr;33(3):225-35. doi: 10.1097/CJI.0b013e3181c01fcb.

PMID:
20445343
[PubMed - indexed for MEDLINE]
10.

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.

Clin Cancer Res. 2010 May 15;16(10):2781-91. doi: 10.1158/1078-0432.CCR-09-3243. Epub 2010 May 11.

PMID:
20460483
[PubMed - indexed for MEDLINE]
Free Article
11.

Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection.

Jarry U, Donnou S, Vincent M, Jeannin P, Pineau L, Fremaux I, Delneste Y, Couez D.

J Neuroimmunol. 2014 Feb 15;267(1-2):35-42. doi: 10.1016/j.jneuroim.2013.12.005. Epub 2013 Dec 12.

PMID:
24369298
[PubMed - indexed for MEDLINE]
12.

TLR ligands in the local treatment of established intracerebral murine gliomas.

Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ.

J Immunol. 2008 Nov 15;181(10):6720-9.

PMID:
18981089
[PubMed - indexed for MEDLINE]
Free Article
13.

Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.

Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.

J Immunother. 2009 Jul-Aug;32(6):622-31. doi: 10.1097/CJI.0b013e3181ab23f1.

PMID:
19483647
[PubMed - indexed for MEDLINE]
14.

IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.

Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML.

J Immunol. 2006 Jul 1;177(1):84-91.

PMID:
16785502
[PubMed - indexed for MEDLINE]
Free Article
15.

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.

Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R.

Blood. 2009 Oct 15;114(16):3431-8. doi: 10.1182/blood-2009-05-223958. Epub 2009 Jul 29.

PMID:
19641184
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.

Roda JM, Parihar R, Carson WE 3rd.

J Immunol. 2005 Aug 1;175(3):1619-27.

PMID:
16034101
[PubMed - indexed for MEDLINE]
Free Article
17.

Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self.

Miska J, Bas E, Devarajan P, Chen Z.

Eur J Immunol. 2012 Oct;42(10):2584-96. doi: 10.1002/eji.201242590. Epub 2012 Aug 10.

PMID:
22777737
[PubMed - indexed for MEDLINE]
18.

Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.

Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.

J Immunother. 2012 May;35(4):344-53. doi: 10.1097/CJI.0b013e318253ec25.

PMID:
22495392
[PubMed - indexed for MEDLINE]
19.

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.

Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R.

J Immunol. 2007 Aug 15;179(4):2493-500.

PMID:
17675511
[PubMed - indexed for MEDLINE]
Free Article
20.

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2.

PMID:
22474386
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk